Omega-3 Fatty Acids for Dementia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the effectiveness of different omega-3 supplements in enhancing brain function in older adults with early memory problems. Researchers are comparing two types of omega-3s, LPC-DHA and TAG-DHA, to determine which better boosts important brain chemicals and improves memory and thinking skills. The study includes a placebo, a harmless pill with no active ingredients, to measure real effects. Older adults who notice memory decline but still manage daily tasks well might be suitable for this trial, especially if they do not consume much fish or regularly take omega-3 supplements. As an unphased trial, this study provides a unique opportunity to contribute to understanding the benefits of omega-3s on brain health.
Will I have to stop taking my current medications?
The trial requires that you do not regularly use medications that might affect the study's outcome or interact with the study product, including anticoagulant medications. If you are taking such medications, you may need to stop them to participate.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that LPC-EPA+DHA supplements are as safe as other common omega-3 supplements, allowing most people to take them without issues. Studies have found that these supplements can increase DHA levels in the brain, which is crucial for brain health. Animal studies suggest they may also aid memory and behavior. Overall, evidence indicates that LPC-EPA+DHA is safe for humans, with no major side effects reported in studies so far.12345
Why are researchers excited about this trial's treatments?
Unlike the standard treatments for dementia, such as cholinesterase inhibitors and memantine, which primarily aim to manage symptoms, LPC-EPA+DHA introduces a novel approach by using omega-3 fatty acids esterified to lysophosphatidylcholine (LPC). This unique formulation is designed to improve the delivery of EPA and DHA, essential fatty acids believed to have neuroprotective effects. Researchers are excited because this method could enhance brain uptake of these fatty acids, potentially offering a new way to support brain health and slow cognitive decline in dementia patients.
What evidence suggests that this trial's treatments could be effective for dementia?
Studies have shown that higher levels of DHA, a type of omega-3 fatty acid, in the blood link to better thinking skills and a lower risk of dementia. Research suggests that LPC-DHA/EPA, a form of omega-3s, can increase DHA levels in the brain and improve memory in animal studies. Additionally, diets rich in LPC-DHA/EPA significantly reduced harmful eye protein levels in Alzheimer's disease models. These findings suggest that LPC-EPA+DHA, which participants in this trial may receive, might improve brain health and memory in people with early signs of cognitive decline. Early evidence supports the idea that LPC-EPA+DHA could be more effective than other omega-3 forms, like TAG-DHA, in achieving these benefits.12467
Who Is on the Research Team?
Robert McNamara, PhD
Principal Investigator
University of Cincinnati
Are You a Good Fit for This Trial?
This trial is for elderly adults showing early signs of cognitive or memory decline, potentially at risk for dementia. Participants should be experiencing mild cognitive impairment or have had a stroke that could lead to dementia.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 24 weeks of supplementation with LPC-DHA or TAG-DHA to assess effects on DHA levels and biomarkers
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LPC-EPA+DHA
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Cincinnati
Lead Sponsor